Trial Profile
Second Line Erlotinib for NSCLC Patients with EGFR Mutation: Our Experience
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 19 Oct 2015
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 19 Oct 2015 New trial record
- 06 Sep 2015 Results presented at the 16th World Conference on Lung Cancer.